Eva Harris

List of Publications by Year
in descending order

234 papers	19,106 citations	10979 71 h-index	15249 126 g-index
247 all docs	247 docs citations	247 times ranked	16694 citing authors

#	Article	IF	Citations
1	The Nicaraguan Pediatric Influenza Cohort Study, 2011â€“2019: Influenza Incidence, Seasonality, and Transmission. Clinical Infectious Diseases, 2023, 76, e1094-e1103.	2.9	5
2	Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. Lancet Infectious Diseases, The, 2022, 22, e42-e51.	4.6	20
3	Clinical Spectrum of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Protection From Symptomatic Reinfection. Clinical Infectious Diseases, 2022, 75, e257-e266.	2.9	33
4	Uncovering the Burden of Dengue in Africa: Considerations on Magnitude, Misdiagnosis, and Ancestry. Viruses, 2022, 14, 233.	1.5	36
5	Homotypic protection against influenza in a pediatric cohort in Managua, Nicaragua. Nature Communications, 2022, 13, 1190.	5.8	7
6	Sulfated Î²-glucan from Agaricus subrufescens inhibits flavivirus infection and nonstructural protein 1-mediated pathogenesis. Antiviral Research, 2022, 203, 105330.	1.9	3
7	Flavivirus NS1 Triggers Tissue-Specific Disassembly of Intercellular Junctions Leading to Barrier Dysfunction and Vascular Leak in a GSK-3Î²-Dependent Manner. Pathogens, 2022, 11, 615.	1.2	13
8	Development and Implementation of Dried Blood Spot-Based COVID-19 Serological Assays for Epidemiologic Studies. Microbiology Spectrum, 2022, 10, .	1.2	9
9	Dengue virus NS1 protein conveys proâ€inflammatory signals by docking onto highâ€density lipoproteins. EMBO Reports, 2022, 23, .	2.0	13
10	Epidemiologic Features of Acute Pediatric Diarrhea in Managua, Nicaragua, from 2011 to 2019. American Journal of Tropical Medicine and Hygiene, 2022, 106, 1757-1764.	0.6	0
11	Association of SARS-CoV-2 Seropositivity and Symptomatic Reinfection in Children in Nicaragua. JAMA Network Open, 2022, 5, e2218794.	2.8	8
12	Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. Science Translational Medicine, 2022, 14, .	5.8	21
13	Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge. PLoS Neglected Tropical Diseases, 2022, 16, e0010588.	1.3	2
14	Individual-level Association of Influenza Infection With Subsequent Pneumonia: A Case-control and Prospective Cohort Study. Clinical Infectious Diseases, 2021, 73, e4288-e4295.	2.9	10
15	Obesity Is Associated With Increased Susceptibility to Influenza A (H1N1pdm) but Not H3N2 Infection. Clinical Infectious Diseases, 2021, 73, e4345-e4352.	2.9	10
16	Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. Journal of Infectious Diseases, 2021, 223, 247-257.	1.9	12
17	Evolution and epidemiologic dynamics of dengue virus in Nicaragua during the emergence of chikungunya and Zika viruses. Infection, Genetics and Evolution, 2021, 92, 104680.	1.0	6
18	Structural basis for antibody inhibition of flavivirus NS1â€“triggered endothelial dysfunction. Science, 2021, 371, 194-200.	6.0	74

#	Article	IF	Citations
19	Developmental outcomes in children exposed to Zika virus in utero from a Brazilian urban slum cohort study. PLoS Neglected Tropical Diseases, 2021, 15, e0009162.	1.3	22
20	Persistence of Anti-ZIKV-IgG over Time Is Not a Useful Congenital Infection Marker in Infants Born to ZIKV-Infected Mothers: The NATZIG Cohort. Viruses, 2021, 13, 711.	1.5	3
21	Boosting can explain patterns of fluctuations of ratios of inapparent to symptomatic dengue virus infections. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
22	Studying the Endothelial Glycocalyx in vitro: What Is Missing?. Frontiers in Cardiovascular Medicine, 2021, 8, 647086.	1.1	20
23	Pre-existing T Cell Memory against Zika Virus. Journal of Virology, 2021, 95, .	1.5	11
24	CyTOF Profiling of Zika and Dengue Virus-Infected Human Peripheral Blood Mononuclear Cells Identifies Phenotypic Signatures of Monotype Subsets and Upregulation of the Interferon-Inducible Protein CD169. MSphere, 2021, 6, e0050521.	1.3	8
25	Previous exposure to dengue virus is associated with increased Zika virus burden at the maternal-fetal interface in rhesus macaques. PLoS Neglected Tropical Diseases, 2021, 15, e0009641.	1.3	20
26	Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections. Frontiers in Immunology, 2021, 12, 703887.	2.2	9
27	Interferon receptor-deficient mice are susceptible to eschar-associated rickettsiosis. ELife, 2021, 10, .	2.8	14
28	The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking De Novo Formation of the Membranous Replication Compartment. Journal of Virology, 2021, 95, e0099621.	1.5	11
29	Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections. Journal of Virology, 2021, 95, e0061921.	1.5	4
30	Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California. JAMA Network Open, 2021, 4, e2124116.	2.8	25
31	Levels of Circulating NS1 Impact West Nile Virus Spread to the Brain. Journal of Virology, 2021, 95, e0084421.	1.5	13
32	A step towards therapeutics for dengue. Nature, 2021, 598, 420-421.	13.7	6
33	Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. Science Translational Medicine, 2021, 13, eabg9478.	5.8	32
34	Viral genome-based Zika virus transmission dynamics in a paediatric cohort during the 2016 Nicaragua epidemic. EBioMedicine, 2021, 72, 103596.	2.7	2
35	Pneumonia Following Symptomatic Influenza Infection Among Nicaraguan Children Before and After Introduction of the Pneumococcal Conjugate Vaccine. Journal of Infectious Diseases, 2021, 224, 643-647.	1.9	1
36	Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate. Journal of Infectious Diseases, 2020, 221, 867-877.	1.9	27

#	Article	IF	Citations
37	Zika Virus Nonstructural Protein 1 Disrupts Glycosaminoglycans and Causes Permeability in Developing Human Placentas. Journal of Infectious Diseases, 2020, 221, 313-324.	1.9	34
38	Assessing the Incidence of Symptomatic Respiratory Syncytial Virus Illness Within a Prospective Birth Cohort in Managua, Nicaragua. Clinical Infectious Diseases, 2020, 70, 2029-2035.	2.9	15
39	Genetic risk for dengue hemorrhagic fever and dengue fever in multiple ancestries. EBioMedicine, 2020, 51, 102584.	2.7	10
40	Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 371-380.	4.6	30
41	In silico drug repurposing for the identification of potential candidate molecules against arboviruses infection. Antiviral Research, 2020, 173, 104668.	1.9	19
42	Avian anti-NS1 IgY antibodies neutralize dengue virus infection and protect against lethal dengue virus challenge. Antiviral Research, 2020, 183, 104923.	1.9	5
43	Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. Current Opinion in Virology, 2020, 43, 59-70.	2.6	41
44	Dengue Immunopathogenesis: A Crosstalk between Host and Viral Factors Leading to Disease: Part I - Dengue Virus Tropism, Host Innate Immune Responses, and Subversion of Antiviral Responses. , 2020, , .		1
45	Migration of Disease. , 2020, , 96-130.		0
46	Zika virus infection enhances future risk of severe dengue disease. Science, 2020, 369, 1123-1128.	6.0	171
47	Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection. Cell Reports, 2020, 31, 107569.	2.9	43
48	Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections. Journal of Infectious Diseases, 2020, 221, 1846-1854.	1.9	29
49	Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. Cell Host and Microbe, 2020, 27, 710-724.e7.	5.1	25
50	FcRn, but not Fcî³Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12943-12951.	3.3	55
51	Cost-effectiveness of community mobilization (Camino Verde) for dengue prevention in Nicaragua and Mexico: A cluster randomized controlled trial. International Journal of Infectious Diseases, 2020, 94, 59-67.	1.5	5
52	T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species. Journal of Virology, 2020, 94, .	1.5	49
53	Primary and Secondary Dengue Virus Infections Elicit Similar Memory B-Cell Responses, but Breadth to Other Serotypes and Cross-Reactivity to Zika Virus Is Higher in Secondary Dengue. Journal of Infectious Diseases, 2020, 222, 590-600.	1.9	17
54	Evaluation of ViroTrack Sero Zika IgG/IgM, a New Rapid and Quantitative Zika Serological Diagnostic Assay. Diagnostics, 2020, 10, 372.	1.3	4

#	Article	IF	Citations
55	Serologic surveillance of maternal Zika infection in a prospective cohort in Leon, Nicaragua during the peak of the Zika epidemic. PLoS ONE, 2020, 15, e0230692.	1.1	8
56	Utility of entomological indices for predicting transmission of dengue virus: secondary analysis of data from the Camino Verde trial in Mexico and Nicaragua. PLoS Neglected Tropical Diseases, 2020, 14, e0008768.	1.3	4
57	Augmented Zika and Dengue Neutralizing Antibodies Are Associated With Guillain-BarrÃ© Syndrome. Journal of Infectious Diseases, 2019, 219, 26-30.	1.9	21
58	HLA Upregulation During Dengue Virus Infection Suppresses the Natural Killer Cell Response. Frontiers in Cellular and Infection Microbiology, 2019, 9, 268.	1.8	12
59	Low seroprevalence rates of Zika virus in Kuala Lumpur, Malaysia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 678-684.	0.7	8
60	Endocytosis of flavivirus NS1 is required for NS1-mediated endothelial hyperpermeability and is abolished by a single N-glycosylation site mutation. PLoS Pathogens, 2019, 15, e1007938.	2.1	61
61	Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. Scientific Reports, 2019, 9, 16258.	1.6	10
62	International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. BMC Pregnancy and Childbirth, 2019, 19, 282.	0.9	18
63	Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. PLoS Medicine, 2019, 16, e1002726.	3.9	130
64	Flavivirus NS1 Triggers Tissue-Specific Vascular Endothelial Dysfunction Reflecting Disease Tropism. Cell Reports, 2019, 26, 1598-1613.e8.	2.9	192
65	ImmuneRegulation: a web-based tool for identifying human immune regulatory elements. Nucleic Acids Research, 2019, 47, W142-W150.	6.5	4
66	Effects of infection history on dengue virus infection and pathogenicity. Nature Communications, 2019, 10, 1246.	5.8	26
67	Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science, 2019, 363, 607-610.	6.0	202
68	Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. Nature Communications, 2019, 10, 938.	5.8	44
69	Molecular Signatures of Dengue Virus-Specific IL-10/IFN-Î³ Co-producing CD4ÂT Cells and Their Association with Dengue Disease. Cell Reports, 2019, 29, 4482-4495.e4.	2.9	35
70	Combination of Nonstructural Protein 1-Based Enzyme-Linked Immunosorbent Assays Can Detect and Distinguish Various Dengue Virus and Zika Virus Infections. Journal of Clinical Microbiology, 2019, 57, .	1.8	24
71	Epidemiological Evidence for Lineage-Specific Differences in the Risk of Inapparent Chikungunya Virus Infection. Journal of Virology, 2019, 93, .	1.5	37
72	The decline of dengue in the Americas in 2017: discussion of multiple hypotheses. Tropical Medicine and International Health, 2019, 24, 442-453.	1.0	50

#	Article	IF	Citations
73	Cyclic Dinucleotideâ€“Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses. Journal of Immunology, 2019, 202, 1153-1162.	0.4	23
74	Reply to GÃ©rardin et al. Clinical Infectious Diseases, 2019, 68, 172-174.	2.9	7
75	Capturing sequence diversity in metagenomes with comprehensive and scalable probe design. Nature Biotechnology, 2019, 37, 160-168.	9.4	96
76	Increased serum sialic acid is associated with morbidity and mortality in a murine model of dengue disease. Journal of General Virology, 2019, 100, 1515-1522.	1.3	10
77	Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses. F1000Research, 2019, 8, 1875.	0.8	6
78	Peptide arrays incubated with three collections of human sera from patients infected with mosquito-borne viruses. F1000Research, 2019, 8, 1875.	0.8	9
79	Diagnosis of Zika Virus Infection by Peptide Array and Enzyme-Linked Immunosorbent Assay. MBio, 2018, 9, .	1.8	70
80	Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. Journal of Infectious Diseases, 2018, 218, 536-545.	1.9	124
81	Zika Virus Replicates in Proliferating Cells in Explants From First-Trimester Human Placentas, Potential Sites for Dissemination of Infection. Journal of Infectious Diseases, 2018, 217, 1202-1213.	1.9	69
82	Precursors of human CD4 ⁺ cytotoxic T lymphocytes identified by single-cell transcriptome analysis. Science Immunology, 2018, 3, .	5.6	209
83	Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. Journal of Clinical Microbiology, 2018, 56, .	1.8	53
84	Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge. EBioMedicine, 2018, 27, 61-70.	2.7	46
85	Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. Journal of Clinical Microbiology, 2018, 56, .	1.8	58
86	Differences in Transmission and Disease Severity Between 2 Successive Waves of Chikungunya. Clinical Infectious Diseases, 2018, 67, 1760-1767.	2.9	29
87	The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection. Current Opinion in Virology, 2018, 29, 51-61.	2.6	14
88	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine, 2018, 36, 3411-3417.	1.7	52
89	Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure. Virus Research, 2018, 254, 27-33.	1.1	48
90	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029371.	2.3	29

#	Article	IF	Citations
91	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 339 adults from Managua, Nicaragua. Human Immunology, 2018, 79, 1-2.	1.2	8
92	Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virusâ€“Specific CD8+ T Cells. Journal of Immunology, 2018, 201, 3487-3491.	0.4	70
93	Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10762-10767.	3.3	26
94	Sequences of Zika Virus Genomes from a Pediatric Cohort in Nicaragua. Genome Announcements, 2018, 6, .	0.8	0
95	Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases. Molecular Systems Biology, 2018, 14, e7862.	3.2	66
96	Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico. Cell Host and Microbe, 2018, 23, 855-864.e7.	5.1	82
97	ELISPOT-Based â€œMulti-Color FluoroSpotâ€•to Study Type-Specific and Cross-Reactive Responses in Memory B Cells after Dengue and Zika Virus Infections. Methods in Molecular Biology, 2018, 1808, 151-163.	0.4	7
98	Obesity Increases the Duration of Influenza A Virus Shedding in Adults. Journal of Infectious Diseases, 2018, 218, 1378-1382.	1.9	178
99	Differing epidemiological dynamics of Chikungunya virus in the Americas during the 2014-2015 epidemic. PLoS Neglected Tropical Diseases, 2018, 12, e0006670.	1.3	23
100	The Good, the Bad, and the Shocking: The Multiple Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis. Annual Review of Virology, 2018, 5, 227-253.	3.0	138
101	Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers. Journal of Infectious Diseases, 2018, 218, 1911-1921.	1.9	13
102	Seroprevalence, risk factor, and spatial analyses of Zika virus infection after the 2016 epidemic in Managua, Nicaragua. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9294-9299.	3.3	78
103	Zika virus infection in Nicaraguan households. PLoS Neglected Tropical Diseases, 2018, 12, e0006518.	1.3	14
104	Internally Controlled, Multiplex Real-Time Reverse Transcription PCR for Dengue Virus and Yellow Fever Virus Detection. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1833-1836.	0.6	13
105	Dengue: knowledge gaps, unmet needs, and research priorities. Lancet Infectious Diseases, The, 2017, 17, e88-e100.	4.6	153
106	Mosquito Biting Modulates Skin Response to Virus Infection. Trends in Parasitology, 2017, 33, 645-657.	1.5	81
107	The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection. EBioMedicine, 2017, 20, 202-216.	2.7	17
108	Rapid and specific detection of Asian- and African-lineage Zika viruses. Science Translational Medicine, 2017, 9, .	5.8	86

#	Article	IF	Citations
109	Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections. Journal of Immunology, 2017, 198, 4025-4035.	0.4	59
110	Influenza and dengue virus coâ€infection impairs monocyte recruitment to the lung, increases dengue virus titers, and exacerbates pneumonia. European Journal of Immunology, 2017, 47, 527-539.	1.6	16
111	CD14+CD16+ monocytes are the main target of Zika virus infection in peripheral blood mononuclear cells in a paediatric study in Nicaragua. Nature Microbiology, 2017, 2, 1462-1470.	5.9	171
112	Antibody-dependent enhancement of severe dengue disease in humans. Science, 2017, 358, 929-932.	6.0	800
113	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. Journal of Virology, 2017, 91, .	1.5	148
114	Association between Haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015. Vaccine, 2017, 35, 6202-6207.	1.7	8
115	A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. Cell, 2017, 171, 229-241.e15.	13.5	118
116	Intrahost Selection Pressures Drive Rapid Dengue Virus Microevolution in Acute Human Infections. Cell Host and Microbe, 2017, 22, 400-410.e5.	5.1	45
117	Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes. MBio, 2017, 8, .	1.8	13
118	Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8384-8389.	3.3	161
119	Camino Verde (The Green Way): evidence-based community mobilisation for dengue control in Nicaragua and Mexico: feasibility study and study protocol for a randomised controlled trial. BMC Public Health, 2017, 17, 407.	1.2	27
120	Immune correlates of protection for dengue: State of the art and research agenda. Vaccine, 2017, 35, 4659-4669.	1.7	81
121	Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests. Clinical Infectious Diseases, 2017, 65, 1829-1836.	2.9	66
122	Zika virus infection of first-trimester human placentas: utility of an explant model of replication to evaluate correlates of immune protection ex vivo. Current Opinion in Virology, 2017, 27, 48-56.	2.6	21
123	Characterization of Dengue Virus Infections Among Febrile Children Clinically Diagnosed With a Non-Dengue Illness, Managua, Nicaragua. Journal of Infectious Diseases, 2017, 215, 1816-1823.	1.9	15
124	Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas. Frontiers in Immunology, 2017, 8, 1309.	2.2	77
125	Dissecting the human serum antibody response to secondary dengue virus infections. PLoS Neglected Tropical Diseases, 2017, 11, e0005554.	1.3	63
126	Dengue occurrence relations and serology: cross-sectional analysis of results from the Guerrero State, Mexico, baseline for a cluster-randomised controlled trial of community mobilisation for dengue prevention. BMC Public Health, 2017, 17, 435.	1.2	6

#	Article	IF	Citations
127	Community cost-benefit discussions that launched the Camino Verde intervention in Nicaragua. BMC Public Health, 2017, 17, 396.	1.2	10
128	Informed community mobilization for dengue prevention in households with and without a regular water supply: Secondary analysis from the Camino Verde trial in Nicaragua. BMC Public Health, 2017, 17, 395.	1.2	6
129	Beyond efficacy in water containers: Temephos and household entomological indices in six studies between 2005 and 2013 in Managua, Nicaragua. BMC Public Health, 2017, 17, 434.	1.2	11
130	Mobilising communities for Aedes aegypti control: the SEPA approach. BMC Public Health, 2017, 17, 403.	1.2	34
131	The Camino Verde intervention in Nicaragua, 2004â€“2012. BMC Public Health, 2017, 17, 406.	1.2	13
132	â€œWhere we put little fish in the water there are no mosquitoes:â€•a cross-sectional study on biological control of the Aedes aegypti vector in 90 coastal-region communities of Guerrero, Mexico. BMC Public Health, 2017, 17, 433.	1.2	14
133	When communities are really in control: ethical issues surrounding community mobilisation for dengue prevention in Mexico and Nicaragua. BMC Public Health, 2017, 17, 410.	1.2	14
134	Preparation of Mosquito Salivary Gland Extract and Intradermal Inoculation of Mice. Bio-protocol, 2017, 7, .	0.2	9
135	Rearing of Culex spp. and Aedes spp. Mosquitoes. Bio-protocol, 2017, 7, .	0.2	49
136	Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement. PLoS Neglected Tropical Diseases, 2017, 11, e0005721.	1.3	26
137	Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components. PLoS Pathogens, 2017, 13, e1006673.	2.1	135
138	Development of in-house serological methods for diagnosis and surveillance of chikungunya. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2017, 41, 1.	0.6	13
139	Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. Emerging Infectious Diseases, 2016, 22, 1295-1297.	2.0	142
140	Metabolomics-Based Discovery of Small Molecule Biomarkers in Serum Associated with Dengue Virus Infections and Disease Outcomes. PLoS Neglected Tropical Diseases, 2016, 10, e0004449.	1.3	53
141	Seroprevalence of Anti-Chikungunya Virus Antibodies in Children and Adults in Managua, Nicaragua, After the First Chikungunya Epidemic, 2014-2015. PLoS Neglected Tropical Diseases, 2016, 10, e0004773.	1.3	37
142	Homotypic Dengue Virus Reinfections in Nicaraguan Children. Journal of Infectious Diseases, 2016, 214, 986-993.	1.9	100
143	Viremia and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus. Clinical Infectious Diseases, 2016, 63, 1584-1590.	2.9	249
144	Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science, 2016, 353, 823-826.	6.0	675

#	Article	IF	Citations
145	Zika Virus Targets Different Primary Human Placental Cells, Suggesting Two Routes for Vertical Transmission. Cell Host and Microbe, 2016, 20, 155-166.	5.1	425
146	Clinical Attack Rate of Chikungunya in a Cohort of Nicaraguan Children. American Journal of Tropical Medicine and Hygiene, 2016, 94, 397-399.	0.6	27
147	Immunodominant Dengue Virus-Specific CD8 ⁺ T Cell Responses Are Associated with a Memory PD-1 ⁺ Phenotype. Journal of Virology, 2016, 90, 4771-4779.	1.5	71
148	Clinical evaluation of a single-reaction real-time RT-PCR for pan-dengue and chikungunya virus detection. Journal of Clinical Virology, 2016, 78, 57-61.	1.6	48
149	Inhibition of endoplasmic reticulum glucosidases is required for inÂvitro and inÂvivo dengue antiviral activity by the iminosugar UV-4. Antiviral Research, 2016, 129, 93-98.	1.9	52
150	Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. Journal of Virology, 2016, 90, 5090-5097.	1.5	30
151	Chikungunya Virus Sequences Across the First Epidemic in Nicaragua, 2014â€“2015. American Journal of Tropical Medicine and Hygiene, 2016, 94, 400-403.	0.6	17
152	Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 728-733.	3.3	156
153	Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization. Journal of Infectious Diseases, 2016, 213, 975-984.	1.9	13
154	Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidasesâ€”Not Glycolipid Processing Enzymes. PLoS Neglected Tropical Diseases, 2016, 10, e0004524.	1.3	69
155	Mosquito Saliva Increases Endothelial Permeability in the Skin, Immune Cell Migration, and Dengue Pathogenesis during Antibody-Dependent Enhancement. PLoS Pathogens, 2016, 12, e1005676.	2.1	86
156	Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability. PLoS Pathogens, 2016, 12, e1005738.	2.1	245
157	The Nicaraguan pediatric influenza cohort study: design, methods, use of technology, and compliance. BMC Infectious Diseases, 2015, 15, 504.	1.3	30
158	Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Severe Dengue Outcome. PLoS Neglected Tropical Diseases, 2015, 9, e0003904.	1.3	54
159	Assessing the epidemiological effect of wolbachia for dengue control. Lancet Infectious Diseases, The, 2015, 15, 862-866.	4.6	73
160	Broad and strong: the ultimate antibody to dengue virus. Nature Immunology, 2015, 16, 135-137.	7.0	13
161	Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity. Journal of Clinical Virology, 2015, 69, 63-67.	1.6	11
162	Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science, 2015, 349, 88-91.	6.0	208

#	Article	IF	Citations
163	Economic and Disease Burden of Dengue in Mexico. PLoS Neglected Tropical Diseases, 2015, 9, e0003547.	1.3	80
164	Yes we can! The Raffles Dialogue on Human Wellbeing and Security. The Lancet Global Health, 2015, 3, e496-e500.	2.9	4
165	Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science, 2015, 350, 217-221.	6.0	338
166	Human CD8⁺T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets. Journal of Infectious Diseases, 2015, 212, 1743-1751.	1.9	129
167	Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Science Translational Medicine, 2015, 7, 304ra141.	5.8	392
168	Evidence based community mobilization for dengue prevention in Nicaragua and Mexico (Camino) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.0	166
169	Introduction and Establishment ofAedes albopictus(Diptera: Culicidae) in Managua, Nicaragua. Journal of Medical Entomology, 2015, 52, 713-718.	0.9	6
170	Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay. Journal of Immunology, 2015, 195, 3490-3496.	0.4	27
171	Dengue viruses cluster antigenically but not as discrete serotypes. Science, 2015, 349, 1338-1343.	6.0	195
172	Dengue. Lancet, The, 2015, 385, 453-465.	6.3	982
173	Infectious Chikungunya Virus in the Saliva of Mice, Monkeys and Humans. PLoS ONE, 2015, 10, e0139481.	1.1	32
174	Technology, innovation and health equity. Bulletin of the World Health Organization, 2015, 93, 438-438A.	1.5	18
175	Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera. PLoS Pathogens, 2014, 10, e1004386.	2.1	144
176	Monocyte Recruitment to the Dermis and Differentiation to Dendritic Cells Increases the Targets for Dengue Virus Replication. PLoS Pathogens, 2014, 10, e1004541.	2.1	97
177	A potent antiâ€dengue human antibody preferentially recognizes the conformation of <scp>E</scp> protein monomers assembled on the virus surface. EMBO Molecular Medicine, 2014, 6, 358-371.	3.3	154
178	Epidemiological Risk Factors Associated with High Global Frequency of Inapparent Dengue Virus Infections. Frontiers in Immunology, 2014, 5, 280.	2.2	144
179	Dendritic Cells in Dengue Virus Infection: Targets of Virus Replication and Mediators of Immunity. Frontiers in Immunology, 2014, 5, 647.	2.2	96
180	Multiplex Nucleic Acid Amplification Test for Diagnosis of Dengue Fever, Malaria, and Leptospirosis. Journal of Clinical Microbiology, 2014, 52, 2011-2018.	1.8	28

#	Article	IF	Citations
181	Innate Immunity to Dengue Virus Infection and Subversion of Antiviral Responses. Journal of Molecular Biology, 2014, 426, 1148-1160.	2.0	189
182	Increased Replicative Fitness of a Dengue Virus 2 Clade in Native Mosquitoes: Potential Contribution to a Clade Replacement Event in Nicaragua. Journal of Virology, 2014, 88, 13125-13134.	1.5	39
183	Regulation of Flavivirus RNA synthesis and replication. Current Opinion in Virology, 2014, 9, 74-83.	2.6	72
184	Monocyte-Plasmablast Crosstalk during Dengue. Cell Host and Microbe, 2014, 16, 7-9.	5.1	8
185	Convergent Antibody Signatures in Human Dengue. Cell Host and Microbe, 2013, 13, 691-700.	5.1	271
186	The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein. MBio, 2013, 4, e00873-13.	1.8	143
187	Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study Year. PLoS Neglected Tropical Diseases, 2013, 7, e2357.	1.3	205
188	The Nicaraguan Pediatric Dengue Cohort Study: Incidence of Inapparent and Symptomatic Dengue Virus Infections, 2004â€“2010. PLoS Neglected Tropical Diseases, 2013, 7, e2462.	1.3	94
189	Single-Reaction, Multiplex, Real-Time RT-PCR for the Detection, Quantitation, and Serotyping of Dengue Viruses. PLoS Neglected Tropical Diseases, 2013, 7, e2116.	1.3	93
190	Evaluation of the Diagnostic Utility of the Traditional and Revised WHO Dengue Case Definitions. PLoS Neglected Tropical Diseases, 2013, 7, e2385.	1.3	45
191	Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in Humans. PLoS Neglected Tropical Diseases, 2013, 7, e2274.	1.3	84
192	Therapeutic Efficacy of Antibodies Lacking FcÎ³R against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies. PLoS Pathogens, 2013, 9, e1003157.	2.1	67
193	Analysis of Cross-Reactive Antibodies Recognizing the Fusion Loop of Envelope Protein and Correlation with Neutralizing Antibody Titers in Nicaraguan Dengue Cases. PLoS Neglected Tropical Diseases, 2013, 7, e2451.	1.3	57
194	Temporal Dynamics of the Transcriptional Response to Dengue Virus Infection in Nicaraguan Children. PLoS Neglected Tropical Diseases, 2012, 6, e1966.	1.3	52
195	Protection from Secondary Dengue Virus Infection in a Mouse Model Reveals the Role of Serotype Cross-Reactive B and T Cells. Journal of Immunology, 2012, 188, 404-416.	0.4	88
196	Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. Journal of General Virology, 2012, 93, 2152-2157.	1.3	114
197	Dominant Cross-Reactive B Cell Response during Secondary Acute Dengue Virus Infection in Humans. PLoS Neglected Tropical Diseases, 2012, 6, e1568.	1.3	91
198	Dengue Reporter Virus Particles for Measuring Neutralizing Antibodies against Each of the Four Dengue Serotypes. PLoS ONE, 2011, 6, e27252.	1.1	66

#	Article	IF	Citations
199	Dynamics of Dengue Disease Severity Determined by the Interplay Between Viral Genetics and Serotype-Specific Immunity. Science Translational Medicine, 2011, 3, 114ra128.	5.8	244
200	Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity. PLoS Neglected Tropical Diseases, 2011, 5, e1397.	1.3	185
201	Unusual Dengue Virus 3 Epidemic in Nicaragua, 2009. PLoS Neglected Tropical Diseases, 2011, 5, e1394.	1.3	28
202	Index Cluster Study of Dengue Virus Infection in Nicaragua. American Journal of Tropical Medicine and Hygiene, 2010, 83, 683-689.	0.6	35
203	Trends in Patterns of Dengue Transmission over 4 Years in a Pediatric Cohort Study in Nicaragua. Journal of Infectious Diseases, 2010, 201, 5-14.	1.9	158
204	Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification. PLoS Pathogens, 2010, 6, e1000790.	2.1	353
205	High Dengue Case Capture Rate in Four Years of a Cohort Study in Nicaragua Compared to National Surveillance Data. PLoS Neglected Tropical Diseases, 2010, 4, e633.	1.3	72
206	The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity. Cell Host and Microbe, 2010, 8, 271-283.	5.1	526
207	Mouse STAT2 Restricts Early Dengue Virus Replication. Cell Host and Microbe, 2010, 8, 410-421.	5.1	156
208	Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2. Journal of Virology, 2010, 84, 9227-9239.	1.5	189
209	The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods, Use of Information Technology, and Extension to Other Infectious Diseases. American Journal of Epidemiology, 2009, 170, 120-129.	1.6	117
210	Poly(A)-binding protein binds to the non-polyadenylated 3â€² untranslated region of dengue virus and modulates translation efficiency. Journal of General Virology, 2009, 90, 687-692.	1.3	124
211	Tropism of Dengue Virus in Mice and Humans Defined by Viral Nonstructural Protein 3-Specific Immunostaining. American Journal of Tropical Medicine and Hygiene, 2009, 80, 416-424.	0.6	199
212	Improvement in Hospital Indicators after Changes in Dengue Case Management in Nicaragua. American Journal of Tropical Medicine and Hygiene, 2009, 81, 287-292.	0.6	27
213	Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. American Journal of Tropical Medicine and Hygiene, 2009, 80, 416-24.	0.6	123
214	Improvement in hospital indicators after changes in dengue case management in Nicaragua. American Journal of Tropical Medicine and Hygiene, 2009, 81, 287-92.	0.6	16
215	Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology, 2008, 376, 429-435.	1.1	190
216	Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. Journal of Clinical Virology, 2008, 43, 287-291.	1.6	59

#	Article	IF	Citations
217	Molecular Biology of Flaviviruses. Novartis Foundation Symposium, 2008, , 23-40.	1.2	61
218	Characterization ofAedes aegypti(Diptera: Culcidae) Production Sites in Urban Nicaragua. Journal of Medical Entomology, 2007, 44, 851-860.	0.9	40
219	High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Tropical Medicine and International Health, 2006, 11, 935-942.	1.0	138
220	Murine Model for Dengue Virus-Induced Lethal Disease with IncreasedVascular Permeability. Journal of Virology, 2006, 80, 10208-10217.	1.5	316
221	SEROTYPE-SPECIFIC DIFFERENCES IN CLINICAL MANIFESTATIONS OF DENGUE. American Journal of Tropical Medicine and Hygiene, 2006, 74, 449-456.	0.6	218
222	Serotype-specific differences in clinical manifestations of dengue. American Journal of Tropical Medicine and Hygiene, 2006, 74, 449-56.	0.6	127
223	Molecular biology of flaviviruses. Novartis Foundation Symposium, 2006, 277, 23-39; discussion 40, 71-3, 251-3.	1.2	40
224	DIFFERENCES IN DENGUE SEVERITY IN INFANTS, CHILDREN, AND ADULTS IN A 3-YEAR HOSPITAL-BASED STUDY IN NICARAGUA. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1063-1070.	0.6	255
225	Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1063-70.	0.6	137
226	Building scientific capacity in developing countries. EMBO Reports, 2004, 5, 7-11.	2.0	96
227	Interferon-Dependent Immunity Is Essential for Resistance to Primary Dengue Virus Infection in Mice, Whereas T- and B-Cell-Dependent Immunity Are Less Critical. Journal of Virology, 2004, 78, 2701-2710.	1.5	287
228	Diagnosis of Dengue Virus Infection by Detection of Specific Immunoglobulin M (IgM) and IgA Antibodies in Serum and Saliva. Vaccine Journal, 2003, 10, 317-322.	3.2	115
229	Infection of Human Cells by Dengue Virus Is Modulated by Different Cell Types and Viral Strains. Journal of Virology, 2000, 74, 7814-7823.	1.5	223
230	Modulation of Dengue Virus Infection in Human Cells by Alpha, Beta, and Gamma Interferons. Journal of Virology, 2000, 74, 4957-4966.	1.5	42
231	Typing of Dengue Viruses in Clinical Specimens and Mosquitoes by Single-Tube Multiplex Reverse Transcriptase PCR. Journal of Clinical Microbiology, 1998, 36, 2634-2639.	1.8	216
232	Epidemics of Chikungunya, Zika, and COVID-19 Reveal Bias in Case-Based Mapping. SSRN Electronic Journal, 0, , .	0.4	0
233	Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses. F1000Research, 0, 8, 1875.	0.8	0
234	Dengue Immunopathogenesis: AÂCrosstalk between Host and Viral Factors Leading to Disease: PART II - DENV Infection, Adaptive Immune Responses, andÂNS1 Pathogenesis. , 0, , .		1